Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add filters








Language
Year range
1.
Chinese Journal of General Surgery ; (12): 120-122, 2001.
Article in Chinese | WPRIM | ID: wpr-411446

ABSTRACT

Objective To evaluate the effect of palliative resection of advanced primary hepatocellular carcinoma (PHCC). Methods 98 patients with advanced PHCC were divided randomly into two groups in our hospital from March 1996 to Jan. 2000:(1) Therapy group (49 cases), dealt with palliative resection of liver cancer and implanted with a drug delivery system (DDS). (2) Control group (49 cases), only implanted with DDS. Results In therapy group and control group, The decline rate of AFP was 60.0% and 31.7% respectively (P<0.05); and the survival rates of 0.5, 1, 3  years after operation were 85.7%  (42/49), 60.5%(23/38), 45.4%(10/22) and  67.3%(33/49), 32.5%(13/40),  10%(2/20) (P<0.05). Conclusions Palliative resection of liver cancer can improve survival duration and life quality of patients with advanced HCC.

2.
Journal of Chinese Physician ; (12)2001.
Article in Chinese | WPRIM | ID: wpr-518735

ABSTRACT

Objective To study the diagnosis and treatment of primary hepatocellular carcinoma(HCC) complicated by intrabile duct obstruction.Methods From Aug.1994 to Feb.2000,the clinical data of 13 HCC patients with intrabile duct obstruction caused by tumor were reviewed.Results There was no operative mortality and all patients were followed up for one year.10 patients were still alive,and one died.Conclusion Jaundice caused by intrabile duct tumor was not a contraindication for hepatectomy.Hepatectomy could gain a longer postoperative survival term.

3.
Chinese Journal of General Surgery ; (12)1993.
Article in Chinese | WPRIM | ID: wpr-521866

ABSTRACT

Objective To evaluate superselective transcatheter arterial chemoembolization ( TACE) plus selective portal vein embolization (SPVE) and large dose of lipiodol on advanced primary liver carcinoma (PHC).Methods Two hundred and three cases of advanced PHC were randomly divided into group treated with ordinary TACE, and that with TACE +SPVE. Results The response rate (CR+PR) was 38% in TACE group and 59% in TACE+SPVE group (P

4.
Chinese Traditional Patent Medicine ; (12)1992.
Article in Chinese | WPRIM | ID: wpr-680973

ABSTRACT

Objective:To investigate the curative effect of Xinbao on patients with sick sinus syndrome(SSS). Methods: 38 patients with SSS were randomly divided into 2 groups: one (A group) taking oral Xinbao and the other (B group) taking xinxianan as control on the base of routine treament. 12 lead surface electrocardiogram and Holter were recorded in all patients before and after treatment. Results: Mean heart rates of the groups were obviously increased after treatment( P 0.05). Conclusion: Xinbao may be a effective and safe drug for treating SSS.

SELECTION OF CITATIONS
SEARCH DETAIL